Roche bolsters liquid biopsy focus with CAPP Medical buy
This article was originally published in Clinica
Executive Summary
The liquid biopsy arena is increasingly hot, and diagnostics giant Roche has taken another step into the space, acquiring CAPP Medical. The Palo Alto, California company has developed technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in the blood.